Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SapRNA-MICA/B in advanced solid tumors
NCT06610227Phase 1Active, not recruiting
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SapRNA-MICA/B Tumor Vaccine Injection in solid tumor (advanced stage). Primary endpoint: Adverse Events at 30 days. Started Nov 2024; status: active, not recruiting.
02
Drugs
SapRNA-MICA/B Tumor Vaccine Injection
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06610227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610227.